Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

evogliptin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Dipeptidyl peptidase 4 (DPP4) is an adipokine that interrupts insulin signaling. The resulting insulin resistance exacerbates… Expand
Is this relevant?
2017
2017
Evogliptin is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of the present study was to evaluate… Expand
  • figure 1
Is this relevant?
2017
2017
Aims This trial consisted of a 24‐week multicentre, randomized, double‐blind, double‐dummy, active‐controlled study and a 52‐week… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2017
2017
Aims To evaluate the efficacy and safety of evogliptin, a newly developed dipeptidyl peptidase‐4 inhibitor, in patients with type… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2016
2016
Although multiple dipeptidyl peptidase 4 (DPP4) inhibitors have shown glucose-lowering effects by preserving pancreatic cells in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
A new fixed-dose combination formulation of evogliptin 5 mg and metformin extended-release (XR) 1,000 mg (FDC_EVO5/MET1000) was… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed… Expand
Is this relevant?
2015
2015
Although dipeptidyl peptidase 4 (DPP4) is an adipokine known to positively correlate with adiposity, the effects of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Evogliptin ((R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)-piperazin-2-one), is a new dipeptidyl… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
Purpose Evogliptin (DA-1229) is a novel, potent, and selective dipeptidyl peptidase IV (DPP-IV) inhibitor in clinical development… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?